Investigation of improved Helicobacter pylori eradication rate using Vonoprazan for first-line therapy: large prospective study.
Not Applicable
- Conditions
- Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000021383
- Lead Sponsor
- TT Medical Center Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with gastric cancer identified by initial gastroduodenal endoscopy Patients who hava allergy to eraducation drugs Patients who have severe diseases affecting the kidney. Patients who have severe diseases affecting the heart. Patients who have severe diseases affecting the liver. Patients judged as inappropriate candidates for the trial by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication rate of Helicobacter pylori
- Secondary Outcome Measures
Name Time Method Changes of abdominal symptom (GSRS) Risk factors for the failure of Helicobacter pylori eradication (Age, Sex, smoking habit, drinking habit, obesity, past history, medication)